Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

16.03 +0.65 (+4.23%)
Streaming Delayed Price Updated: 1:30 PM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug ↗
The company is testing a gene therapy for Huntington's disease and could soon seek an accelerated approval. 
Via Investor's Business Daily
News headline image
Why Is uniQure Stock Skyrocketing On Tuesday? ↗
uniQure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130. 
Via Benzinga
News headline image
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
From uniQure Inc.
Via GlobeNewswire
CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
Via AB Newswire
Topics Intellectual Property
News headline image
QURE Stock Earnings: uniQure Beats EPS, Beats Revenue for Q2 2024 ↗
QURE stock results show that uniQure beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
From uniQure Inc.
Via GlobeNewswire
News headline image
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Why Are UniQure Shares Surging Today? ↗
UniQure N.V. (NASDAQ: QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's... 
Via Benzinga
News headline image
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
SMART Global Posts Upbeat Results, Joins Aehr Test Systems, MarineMax And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
S&P 500 Edges Higher; Indivior Shares Plummet ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Crude Oil Down 1%; Soligenix Shares Surge ↗
 
Via Benzinga
News headline image
Why UniQure Stock Is Soaring ↗
UniQure shares are trading higher Tuesday after the company announced updated interim data from its ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington's... 
Via Benzinga
News headline image
MULN Stock Alert: Mullen Announces EV Sale to Spencer Manufacturing ↗
Mullen stock is down on Tuesday even as MULN shareholders learn of a new EV order for subsidiary Bollinger Motors from Spencer Manufacturing. 
Via InvestorPlace
News headline image
Why Is uniQure (QURE) Stock Up 51% Today? ↗
UniQure stock is up on Tuesday as QURE investors react to positive clinical trial data for its Huntington’s Disease treatment candidate. 
Via InvestorPlace
News headline image
Dow Falls Over 50 Points; US Small Business Optimism Surges In June ↗
 
Via Benzinga
Topics Stocks
News headline image
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
QURE Stock Earnings: uniQure Misses EPS, Beats Revenue for Q1 2024 ↗
QURE stock results show that uniQure missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy ↗
Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure. 
Via Investor's Business Daily
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.